Full TitleSmoldering Myeloma Registration Trial (SMRT study) (NYU)
The purpose of this research study is to understand more about smoldering multiple myeloma (SMM). SMM is multiple myeloma that is not yet causing symptoms. It is usually not treated unless it causes symptoms.
In this study, researchers are looking at some of the racial differences in SMM. They are seeing how the transformation of SMM to multiple myeloma with symptoms differs between European Americans and African Americans. In addition, they are looking at the specific features of SMM transformation at the level of molecules. They want to see how these features differ among European Americans and African Americans.
If you join this study, you will be in it for 10 years and have about 10 study visits. Researchers will take samples of your blood, bone marrow, and stool to study biomarkers and do genomic sequencing of myeloma cells. A biomarker is a molecule that is a sign of a normal or abnormal condition or disease. It may be used to see how the body responds to treatment for a disease or condition. Genomic sequencing looks at the order (sequence) of your genes and proteins. It is used to see if you have genetic mutations (changes or variants) that may increase your risk of disease.
Who Can Join
To join this study, there are a few conditions. You must:
- Have SMM.
- Have not received prior treatment for myeloma.
- Be willing to provide blood, bone marrow, and stool samples.
- Be age 18 or older.
For more information or to see if you can join this study, please call Dr. Alexander Lesokhin’s office at 646-608-3717.